A phase I study of the Dz13 drug targeting the c-Jun gene in subjects with skin cance (nodular Basal Cell Carcinoma).
Phase 1
Completed
- Conditions
- odular Basal Cell Carcinoma (BCC)Nodular Basal Cell Carcinoma (BCC)Cancer - Non melanoma skin cancer
- Registration Number
- ACTRN12610000162011
- Lead Sponsor
- niversity of New South Wales
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Histologically proven nodular BCC.
Measurable disease of 8-16 mm located on trunk or limbs.
Presence of dividing cells as identified histologically.
Exclusion Criteria
Women of childbearing potential.
Prior or co-existing malignancy.
Radiotherapy to >30% bone marrow in previous three months.
Known genetic predisposition to skin cancer.
Clinically significant non-malignant disease.
Current immunosuppression.
History of immune-mediated thrombocytopenia or other platelet disease.
History of drug abuse.
Enrollment in another clinical study using another investigational agent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method